CN105339798A - 利用蛋白质聚集物的解离来诊断与异常蛋白质聚集或错误折叠相关之疾病的诊断试剂盒 - Google Patents
利用蛋白质聚集物的解离来诊断与异常蛋白质聚集或错误折叠相关之疾病的诊断试剂盒 Download PDFInfo
- Publication number
- CN105339798A CN105339798A CN201480036335.7A CN201480036335A CN105339798A CN 105339798 A CN105339798 A CN 105339798A CN 201480036335 A CN201480036335 A CN 201480036335A CN 105339798 A CN105339798 A CN 105339798A
- Authority
- CN
- China
- Prior art keywords
- protein
- disease
- amyloid
- illness
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C=CC1CCC(CCCS(*)(=O)=O)CC1 Chemical compound *C=CC1CCC(CCCS(*)(=O)=O)CC1 0.000 description 1
- BMDVMZFJAPDWOC-UHFFFAOYSA-N CCCC1CCC(CCCS(O)(=O)=O)CC1 Chemical compound CCCC1CCC(CCCS(O)(=O)=O)CC1 BMDVMZFJAPDWOC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6827—Total protein determination, e.g. albumin in urine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Ecology (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dispersion Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (26)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810037524.6A CN108089012A (zh) | 2013-04-26 | 2014-04-25 | 利用蛋白质聚集物的解离来诊断与异常蛋白质聚集或错误折叠相关之疾病的诊断试剂盒 |
CN201810037521.2A CN108387738B (zh) | 2013-04-26 | 2014-04-25 | 利用蛋白质聚集物的解离来诊断与异常蛋白质聚集或错误折叠相关之疾病的诊断试剂盒 |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361816343P | 2013-04-26 | 2013-04-26 | |
US61/816,343 | 2013-04-26 | ||
KR1020140038989A KR20140128230A (ko) | 2013-04-26 | 2014-04-02 | 혈액 중 단백질 응집체의 용해를 통한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 진단키트 |
KR10-2014-0038989 | 2014-04-02 | ||
KR10-2014-0038988 | 2014-04-02 | ||
KR1020140038988A KR20140128229A (ko) | 2013-04-26 | 2014-04-02 | 체내 단백질 응집체의 용해를 이용한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 혈액진단키트 |
PCT/KR2014/003643 WO2014175693A1 (ko) | 2013-04-26 | 2014-04-25 | 단백질 응집체의 용해를 이용한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 진단키트 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810037521.2A Division CN108387738B (zh) | 2013-04-26 | 2014-04-25 | 利用蛋白质聚集物的解离来诊断与异常蛋白质聚集或错误折叠相关之疾病的诊断试剂盒 |
CN201810037524.6A Division CN108089012A (zh) | 2013-04-26 | 2014-04-25 | 利用蛋白质聚集物的解离来诊断与异常蛋白质聚集或错误折叠相关之疾病的诊断试剂盒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105339798A true CN105339798A (zh) | 2016-02-17 |
Family
ID=52452150
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810037521.2A Active CN108387738B (zh) | 2013-04-26 | 2014-04-25 | 利用蛋白质聚集物的解离来诊断与异常蛋白质聚集或错误折叠相关之疾病的诊断试剂盒 |
CN201480036335.7A Pending CN105339798A (zh) | 2013-04-26 | 2014-04-25 | 利用蛋白质聚集物的解离来诊断与异常蛋白质聚集或错误折叠相关之疾病的诊断试剂盒 |
CN201810037524.6A Pending CN108089012A (zh) | 2013-04-26 | 2014-04-25 | 利用蛋白质聚集物的解离来诊断与异常蛋白质聚集或错误折叠相关之疾病的诊断试剂盒 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810037521.2A Active CN108387738B (zh) | 2013-04-26 | 2014-04-25 | 利用蛋白质聚集物的解离来诊断与异常蛋白质聚集或错误折叠相关之疾病的诊断试剂盒 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810037524.6A Pending CN108089012A (zh) | 2013-04-26 | 2014-04-25 | 利用蛋白质聚集物的解离来诊断与异常蛋白质聚集或错误折叠相关之疾病的诊断试剂盒 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10006920B2 (zh) |
EP (1) | EP2990801B1 (zh) |
JP (1) | JP6189526B2 (zh) |
KR (9) | KR20140128230A (zh) |
CN (3) | CN108387738B (zh) |
WO (1) | WO2014175693A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107303411A (zh) * | 2016-04-19 | 2017-10-31 | 南京中硼联康医疗科技有限公司 | 用于消除β淀粉样蛋白沉积斑块的中子捕获治疗系统 |
CN110869763A (zh) * | 2017-05-16 | 2020-03-06 | 安培里翁公司 | 错误折叠tau蛋白质的检测 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017138696A1 (ko) * | 2016-02-12 | 2017-08-17 | 주식회사 캔티스 | 단백질 응집형의 검출 방법, 전기화학적 검출 키트 및 이를 이용한 비정상 단백질 응집 관련 질병의 진단 방법 및 전기화학적 진단 키트 |
KR101934475B1 (ko) | 2017-06-12 | 2019-01-02 | 연세대학교 산학협력단 | 타우린 포함 단백질 단량체화 조성물 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000068694A1 (en) * | 1999-05-07 | 2000-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Method for diagnosis of alzheimer's disease |
CN1809352A (zh) * | 2003-05-15 | 2006-07-26 | 罗斯坎普研究有限公司 | 减少淀粉样沉积、淀粉样神经毒性和小胶质增生的方法 |
US20110144111A1 (en) * | 2009-12-11 | 2011-06-16 | Dong Jin Kim | Pharmaceutical composition for preventing or treating diseases associated with beta-amyloid accumulation containing morpholin or piperazine based compounds having so3h or cooh as active ingredient |
CN102666577A (zh) * | 2009-11-24 | 2012-09-12 | 前体生物药物股份公司 | 诊断阿尔茨海默病或轻度认知损害的新的诊断方法 |
CN102713633A (zh) * | 2009-12-11 | 2012-10-03 | 艾拉科隆生物技术公司 | 用于β-淀粉样肽的改进检测的方法和试剂 |
CN102713622A (zh) * | 2010-01-28 | 2012-10-03 | 松下电器产业株式会社 | β淀粉样蛋白的测定方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7427392B1 (en) * | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
KR100595494B1 (ko) * | 2003-02-24 | 2006-07-03 | (주) 디지탈바이오텍 | 혈액 내 베타-아밀로이드 항체 농도를 이용한 알츠하이머병 진단키트 |
JP2005104975A (ja) * | 2003-09-09 | 2005-04-21 | Takeda Chem Ind Ltd | 抗体の用途 |
BRPI0513959A (pt) * | 2004-07-30 | 2008-05-20 | Rinat Neuroscience Corp | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos |
EP1820019A4 (en) * | 2004-11-12 | 2008-05-14 | Pfizer | METHOD FOR MEASURING BETA-AMYLOID PEPTIDES |
WO2007103683A2 (en) | 2006-03-01 | 2007-09-13 | Roskamp Research Llc | Compounds for inhibiting beta-amyloid production |
KR20120116416A (ko) * | 2009-11-30 | 2012-10-22 | 노파르티스 아게 | 뇌척수액에서 알츠하이머 병에 대한 생체 마커로서의 아밀로이드 베타 응집체 |
CN104662423A (zh) * | 2012-03-13 | 2015-05-27 | 杨森阿尔茨海默氏症免疫治疗公司 | 阿兹海默氏病的诊断、预后和监测中的寡聚体Aβ |
-
2014
- 2014-04-02 KR KR1020140038989A patent/KR20140128230A/ko active Search and Examination
- 2014-04-02 KR KR1020140038988A patent/KR20140128229A/ko active Search and Examination
- 2014-04-25 KR KR1020140050001A patent/KR101619238B1/ko active IP Right Grant
- 2014-04-25 CN CN201810037521.2A patent/CN108387738B/zh active Active
- 2014-04-25 US US14/787,146 patent/US10006920B2/en active Active
- 2014-04-25 CN CN201480036335.7A patent/CN105339798A/zh active Pending
- 2014-04-25 EP EP14788047.0A patent/EP2990801B1/en active Active
- 2014-04-25 CN CN201810037524.6A patent/CN108089012A/zh active Pending
- 2014-04-25 KR KR1020140050002A patent/KR101621935B1/ko active IP Right Grant
- 2014-04-25 WO PCT/KR2014/003643 patent/WO2014175693A1/ko active Application Filing
- 2014-04-25 JP JP2016510622A patent/JP6189526B2/ja not_active Expired - Fee Related
-
2015
- 2015-11-30 KR KR1020150169084A patent/KR20150139487A/ko not_active Application Discontinuation
- 2015-12-08 KR KR1020150173690A patent/KR20150141925A/ko not_active Application Discontinuation
-
2017
- 2017-02-23 KR KR1020170024145A patent/KR20170024600A/ko not_active Application Discontinuation
- 2017-02-23 KR KR1020170024146A patent/KR20170023915A/ko not_active Application Discontinuation
-
2019
- 2019-11-05 KR KR1020190140267A patent/KR20190126754A/ko active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000068694A1 (en) * | 1999-05-07 | 2000-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Method for diagnosis of alzheimer's disease |
CN1809352A (zh) * | 2003-05-15 | 2006-07-26 | 罗斯坎普研究有限公司 | 减少淀粉样沉积、淀粉样神经毒性和小胶质增生的方法 |
CN102666577A (zh) * | 2009-11-24 | 2012-09-12 | 前体生物药物股份公司 | 诊断阿尔茨海默病或轻度认知损害的新的诊断方法 |
US20110144111A1 (en) * | 2009-12-11 | 2011-06-16 | Dong Jin Kim | Pharmaceutical composition for preventing or treating diseases associated with beta-amyloid accumulation containing morpholin or piperazine based compounds having so3h or cooh as active ingredient |
CN102713633A (zh) * | 2009-12-11 | 2012-10-03 | 艾拉科隆生物技术公司 | 用于β-淀粉样肽的改进检测的方法和试剂 |
CN102713622A (zh) * | 2010-01-28 | 2012-10-03 | 松下电器产业株式会社 | β淀粉样蛋白的测定方法 |
Non-Patent Citations (2)
Title |
---|
HYE YUN KIM等: "Regulation of in vitro Aβ1−40 aggregation mediated by small molecules", 《JOURNAL OF ALZHEIMER"S DISEASE》 * |
J.RANDALL SLEMMON等: "Distribution of Aβ peptide in whole blood", 《JOURNAL OF CHROMATOGRAPHY B》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107303411A (zh) * | 2016-04-19 | 2017-10-31 | 南京中硼联康医疗科技有限公司 | 用于消除β淀粉样蛋白沉积斑块的中子捕获治疗系统 |
CN107303411B (zh) * | 2016-04-19 | 2020-04-14 | 南京中硼联康医疗科技有限公司 | 用于消除β淀粉样蛋白沉积斑块的中子捕获治疗系统 |
CN110869763A (zh) * | 2017-05-16 | 2020-03-06 | 安培里翁公司 | 错误折叠tau蛋白质的检测 |
Also Published As
Publication number | Publication date |
---|---|
CN108387738A (zh) | 2018-08-10 |
KR20140128265A (ko) | 2014-11-05 |
KR101621935B1 (ko) | 2016-05-17 |
JP6189526B2 (ja) | 2017-08-30 |
CN108387738B (zh) | 2020-08-11 |
KR20190126754A (ko) | 2019-11-12 |
KR20170024600A (ko) | 2017-03-07 |
KR20140128229A (ko) | 2014-11-05 |
KR20150139487A (ko) | 2015-12-11 |
US10006920B2 (en) | 2018-06-26 |
KR101619238B1 (ko) | 2016-05-10 |
US20160103139A1 (en) | 2016-04-14 |
WO2014175693A1 (ko) | 2014-10-30 |
KR20140128230A (ko) | 2014-11-05 |
EP2990801A1 (en) | 2016-03-02 |
JP2016537609A (ja) | 2016-12-01 |
KR20170023915A (ko) | 2017-03-06 |
EP2990801A4 (en) | 2016-11-30 |
KR20150141925A (ko) | 2015-12-21 |
KR20140128266A (ko) | 2014-11-05 |
CN108089012A (zh) | 2018-05-29 |
EP2990801B1 (en) | 2019-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Craft et al. | Effects of regular and long-acting insulin on cognition and Alzheimer’s disease biomarkers: a pilot clinical trial | |
Sarkozy et al. | LAMA2-related dystrophies: clinical phenotypes, disease biomarkers, and clinical trial readiness | |
Ott et al. | Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease | |
Moore et al. | Case study: Caudate glutamatergic changes with paroxetine therapy for pediatric obsessive‐compulsive disorder | |
Nishioka et al. | Diffusion tensor imaging reveals visual pathway damage in patients with mild cognitive impairment and Alzheimer's disease | |
Bjorkli et al. | Bridging the gap between fluid biomarkers for Alzheimer’s disease, model systems, and patients | |
Ren et al. | Longitudinal alteration of intrinsic brain activity in the striatum in mild cognitive impairment | |
CN105339798A (zh) | 利用蛋白质聚集物的解离来诊断与异常蛋白质聚集或错误折叠相关之疾病的诊断试剂盒 | |
Lamar et al. | Down syndrome with and without dementia: an in vivo proton magnetic resonance spectroscopy study with implications for Alzheimer's disease | |
Loehr et al. | Eliminating Nox2 reactive oxygen species production protects dystrophic skeletal muscle from pathological calcium influx assessed in vivo by manganese‐enhanced magnetic resonance imaging | |
Hlusicka et al. | MRI-based brain volumetry and retinal optical coherence tomography as the biomarkers of outcome in acute methanol poisoning | |
Larsson et al. | Adult patients with “asymptomatic” and “compensated” hydrocephalus benefit from surgery | |
JP5850374B2 (ja) | アルツハイマー病の診断補助方法、及び診断システム | |
Sheng et al. | Dissection of prodromal Alzheimer's disease | |
Fox-Rawlings et al. | NCHR report: the health risks of MRIs with gadolinium-based contrast agents | |
Konno et al. | Clinical significance of mammillary body enhancement in Wernicke encephalopathy: report of 2 cases and review of the literature | |
Yao et al. | Core-Centered Connection Abnormalities Associated with Pathological Features Mediate the Progress of Cognitive Impairments in Alzheimer’s Disease Spectrum Patients | |
Chen et al. | Acute hearing loss in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) | |
US9775920B2 (en) | Use of N-(4-isopropylphenyl)-5-amino-isoindoline | |
Antioch et al. | Current knowledge of pain involvement in Alzheimers disease | |
Wang et al. | Reversible lesion involving the splenium of the corpus callosum caused by phenytoin sodium withdrawal | |
Mumtaz et al. | Comparison of Telmisartan and Verapamil in Reducing Proteinuria in Diabetic Nephropathy Patients | |
Gupta et al. | AWP/N1/229 | |
KR20200051398A (ko) | 치매 진단을 위한 비강 분비물 내 단백질 분석 장치 및 방법 | |
RU2520658C1 (ru) | Способ определения эффективности проводимой противопанкреатической терапии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Jin Yongxiu Inventor after: Gao Zaiying Inventor after: Jin Dongchen Inventor after: Jin Huiyuan Inventor after: Cao Xiumin Inventor after: Jin Taisong Inventor after: Jin Xianzhen Inventor after: Li Shizhen Inventor after: Huang Jiaoshan Inventor after: Lu Zhixun Inventor before: Jin Yongxiu Inventor before: Jin Dongchen Inventor before: Jin Huiyuan Inventor before: Cao Xiumin Inventor before: Jin Taisong Inventor before: Jin Xianzhen Inventor before: Li Shizhen |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160217 |